Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O43598
UPID:
DNPH1_HUMAN
Alternative names:
c-Myc-responsive protein RCL
Alternative UPACC:
O43598; B2LUJ9
Background:
2'-deoxynucleoside 5'-phosphate N-hydrolase 1, also known as c-Myc-responsive protein RCL, plays a crucial role in nucleotide metabolism by catalyzing the cleavage of the N-glycosidic bond of deoxyribonucleoside 5'-monophosphates. This process yields deoxyribose 5-phosphate and a base, with a preference for purine bases over pyrimidine bases.
Therapeutic significance:
Understanding the role of 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 could open doors to potential therapeutic strategies.